Breast Cancer Press releases

Monday May 30, 2011

IPSOGEN to present two studies on the Genomic Grade at ASCO 2011 in Chicago, Ill, USA

IPSOGEN SA (Alternext: ALIPS) today announces that two studies on the Genomic Grade test will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting, that will take place June 3-7, 2011, in Chicago, Ill, USA. The Genomic Grade test (GG), a multi-gene expression test, improv...[more]

Category: Breast Cancer

Monday May 02, 2011

IPSOGEN to present a study on Genomic Grade in Lobular Carcinoma at the 3rd IMPAKT Breast Conference in Brussels, Belgium

IPSOGEN (Alternext – FR0010626028 - ALIPS), a cancer “profiler” that develops, manufactures and markets molecular diagnostic tests for leukemia and breast cancer, today announces that a study on Genomic Grade will be presented at the 3rd IMPAKT Breast Cancer Conference, taking place May 5-7, 2011, i...[more]

Category: Breast Cancer

Tuesday December 07, 2010

Three New Studies on Genomic Grade at 33rd Annual San Antonio Breast Cancer Symposium

IPSOGEN SA (Alternext: ALIPS) today announced that three studies on Genomic Grade will be presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS), taking place December 8-12, 2010, at the Henry B. Gonzalez Convention Center. The Genomic Grade (GGI), a multi-gene expression test, all...[more]

Category: Breast Cancer

Monday January 11, 2010

The Institut Curie and IPSOGEN sign a scientific collaboration agreement relating to the Genomic Grade, a molecular diagnostic tool for breast cancer

Paris, Marseille, January 11, 2010 - The INSTITUT CURIE and IPSOGEN (FR0010626028 - ALIPS) announce the signing of a scientific collaboration agreement in the breast cancer domain. Within the framework of this project, the current scientific knowledge on Ipsogen’s MapQuant Dx Grade Genomic, HER2 and...[more]

Category: Breast Cancer

Monday December 21, 2009

Institut Paoli Calmettes and IPSOGEN presented a new study supporting the pivotal role of tumor grade in chemotherapy prescription at the 32nd Annual San Antonio Breast Cancer Symposium

The study reinforces tumor grade as the most contributive factor for adjuvant chemotherapy in N-/M- IBC, together with tumor size[more]

Category: Breast Cancer

Friday July 10, 2009

Ipsogen reports incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer

The St Gallen Consensus Meeting specifies that Genomic Grade could be considered as an adjunct to histological grading[more]

Category: Breast Cancer